AstraZeneca's ATTR-CM trial failure raises broader questions about silencer drugs
AstraZeneca (AZN) has laid out in detail the surprise failure of a closely watched heart disease trial, revealing how its experimental drug offered no additional benefit to patients who were largely already taking a rival class of medicine…
